Background. Stimulators applying functional electrical stimulation (FES) to the common peroneal nerve improve walking with a foot drop, which occurs in several disorders. Objective. To compare the orthotic and therapeutic effects of a foot drop stimulator on walking performance of subjects with chronic nonprogressive (eg, stroke) and progressive (eg, multiple sclerosis) disorders. Methods. Subjects with nonprogressive (41) and progressive (32) conditions used a foot drop stimulator for 3 to 12 months while walking in the community. Walking speed was measured with a 10-m test and a 4-minute figure-8 test; physiological cost index (PCI) and device usage were also measured. The subjects were tested with FES on and off (orthotic effect) before and after (therapeutic effect) stimulator use. Results. After 3 months of FES use, the nonprogressive and progressive groups had a similar, significant orthotic effect (5.0% and 5.7%, respectively, P < .003; percentage change in mean values) and therapeutic effect with FES off (17.8% and 9.1%, respectively, P < .005) on figure-8 walking speed. Overall, PCI showed a decreasing trend (P = .031). The therapeutic effect on figure-8 speed diverged later between both groups to 28.0% (P < .001) and 7.9% at 11 months. The combined therapeutic plus orthotic effect on figure-8 speed at 11 months was, respectively, 37.8% (P < .001) and 13.1% (P = .012); PCI decreased 18.2% (P = .038) and 6.5%, respectively. Conclusions. Subjects with progressive and nonprogressive disorders had an orthotic benefit from FES up to 11 months. The therapeutic effect increased for 11 months in nonprogressive disorders but only for 3 months in progressive disorders. The combined effect remained significant and clinically relevant.
Introduction
Foot drop is a common symptom in various disorders of the central nervous system (CNS), such as stroke, multiple sclerosis (MS), and incomplete spinal cord injury (SCI). Foot drop results from weakness or lack of voluntary control in the ankle and toe dorsiflexor muscles. Concomitant spasticity of antagonistic calf muscles may further limit ankle dorsiflexion, and often synergistic knee and hip flexor muscles are weak. As a result, the foot drops and the toes may not clear the floor during the swing phase of walking. [1] [2] [3] Disruption of the normal gait pattern may reduce walking speed, decrease walking endurance, and cause trips and falls. The conventional approach to treating foot drop has been the application of an ankle-foot orthosis (AFO). An AFO holds the ankle passively at about 90° and prevents the foot from dropping during the swing phase. Although an AFO mitigates some of the walking difficulty, it may not provide enough assistance, especially when the hip flexors are also weak. 4 As an AFO passively limits ankle movement, it may stiffen the ankle joint and result in contractures of the plantar flexors. In addition, AFOs may have practical drawbacks because of size and weight and are not cosmetically appealing. Two different sizes of shoes may be needed.
An alternative approach is to apply functional electrical stimulation (FES) to the common peroneal (CP) nerve during the swing phase of the gait cycle. Through electrical stimulation the ankle can be flexed beyond 90°, which helps the toes to clear the floor during the initiation of the swing phase. Depending on the placement of the electrodes, ankle dorsiflexion will be associated with more or less eversion. The added eversion in the swing phase increases ankle stability during the next foot contact, as people with a foot drop often tend to invert and land on the lateral border of the foot. In addition, the stimulation may inhibit antagonists such as the calf muscles and assist flexion at other joints through a flexor reflex (withdrawal reflex). [5] [6] [7] [8] The clinical benefits of FES devices to enhance gait can be evaluated by comparing walking speed or other gait parameters with and without nerve stimulation. 4, [9] [10] [11] The immediate change in gait with FES on, compared with FES off, is sometimes referred to as the orthotic effect, 12, 13 because FES mimics the effect of an AFO in helping to clear the foot over the ground.
In addition to the orthotic effect, which is related to improved biomechanics of walking, foot drop stimulators also seem to have a physiological effect on voluntary ankle movement. Since Liberson et al 5 first applied FES, several studies have noted that some hemiplegic subjects who used electrical stimulation improved their walking function, even after the stimulation was turned off. This phenomenon received the name carryover effect, because it was initially reported as a short-lasting (minutes) effect of the electrical stimulation. Subsequent studies have shown that the so-called carryover effect may increase over time with long-term and repeated use. 9, 11, 13, 14 In more recent studies, the change in walking performance over time, measured while FES is off, has been referred to as a therapeutic effect, [15] [16] [17] [18] a term that seems more appropriate for the changes associated with long-term FES use. The total effect of the FES is the sum of the orthotic and therapeutic effects. There have been a number of studies on the effects of peroneal nerve stimulators, mainly on people with stroke, and some of the results have been summarized in 3 review articles. 15, 17, 19 All studies found an orthotic effect of using a foot drop stimulator. Studies on people with stroke generally described a therapeutic effect, but 2 randomized control trials did not confirm this result. 9, 16 In contrast, the occurrence of a therapeutic effect in chronic progressive diseases, such as MS, remains obscure. Taylor et al 12 found no therapeutic effect for the MS group as a whole, although 3 out of 21 subjects showed a clinically relevant therapeutic effect.
We previously reported results from 26 subjects with mainly nonprogressive disorders. 14 In that earlier study differences between nonprogressive and progressive groups could not be analyzed because there were too few subjects with progressive disorders. Therefore, we subsequently enrolled more subjects, most of whom had progressive disorders. All subjects had their conditions for at least 6 months, so no spontaneous recovery without using FES was expected. The present study includes the 26 subjects from the preliminary study mentioned above.
The study on these chronic subjects was designed to answer several questions:
1. Do people with generally nonprogressive conditions experience a therapeutic effect, whereas people with progressive conditions only have an orthotic effect? This question is important because the therapeutic effect of FES may be an indication of plasticity in the CNS and lead to long-term improvement in the motor capacity of the affected limb. 2. What is the time course of the orthotic and therapeutic changes? Most previous studies only examined a single time point before and between 3 and 6.5 months after starting FES. In a progressive disorder there may be a therapeutic benefit at one time that disappears as the progression of the disease continues, so studying the full time course is required. 3. All subjects used a prototype of a new foot drop stimulator with an integrated tilt sensor that is now available commercially (WalkAide; Innovative Neurotronics, Austin, TX). Previous studies from other groups used devices with heel switch control. How successful is the tilt sensor in obtaining adequate control of the timing of stimulation? In this article, we describe the changes in walking performance in relation to these questions. A companion article focuses on possible central mechanisms underlying the therapeutic effect by testing corticospinal excitability using transcranial magnetic stimulation before and after using the foot drop stimulator.
Methods Subjects
Subjects were included who had a foot drop resulting from progressive and nonprogressive CNS disorders and were in a chronic stage, that is, at least 6 months after the onset of the disorder. A test-retest design was used, wherein each subject is measured with and without a foot drop stimulator at various intervals to allow the magnitude of the therapeutic and orthotic effects to be calculated separately.
As described in the Introduction, the difference (FES On -FES Off) at a given time is referred to as an orthotic effect. The difference between FES Off before and after a period of FES use is referred to as a therapeutic effect.
Inclusion focused on the dysfunction related to foot drop rather than on specific diagnosis; therefore, people with various disorders causing a foot drop were included: for example, stroke, incomplete SCI, brain injury, and MS. Additional criteria for inclusion in the trial were (1) adults aged 18 years or older; (2) inadequate dorsiflexion during the swing phase of gait, resulting in inadequate limb clearance; (3) medical referral to participate; (4) adequate cognitive and communication function to give informed consent, understand the training instructions, use the device, and give feedback; (5) ability to ambulate at least 10 m with or without a portable assistive device (eg, walker, crutch, cane, but no parallel bars). Exclusion criteria were (1) lower motor neuron injury with inadequate response to stimulation; (2) history of falls greater than once a week; (3) severe cardiac disease such as myocardial infarction, congestive heart failure, or a demand pacemaker; (4) fixed ankle contractures of >5° of plantar flexion with knee extended; (5) ambulation velocity greater than 1.2 m/s; (6) 
Study Design
Subjects gave their written, informed consent to participate in the trial in accordance with the human ethics committees of the participating institutions. During the first session, subjects were fitted with a WalkAide foot drop stimulator, and baseline walking data were collected. The subjects usually came back on a second day for training on how to use the WalkAide. Then, they took the WalkAide and started using it on a daily basis at home and for walking in the community. All subjects came back for testing after 1, 2, and 3 months. After 3 months most subjects wanted to continue to use the WalkAide. However, because of the costs, distances involved (some subjects lived up to 2000 km from the participating centers), and availability of devices, some subjects could not continue for longer periods of time.
Those who could continue were tested at 6 months and, where possible, at about 12 months. Throughout their participation in the trial, the use of medications relevant to foot drop (eg, antispasticity drugs) was documented. The subjects were asked to maintain their medications constant, as far as possible, and not to start other therapies such as botulinum toxin (Botox).
WalkAide Foot Drop Stimulator
The WalkAide consists of a single-channel stimulator mounted on a cuff that fits around the upper part of the shank and calf. Two round, hydrogel electrodes (diameter 3.2 cm) are attached to the inside of the cuff with Velcro. The active electrode is typically positioned over the CP nerve just distal and dorsal to the head of the fibula, whereas the indifferent electrode is placed over the tibialis anterior muscle belly. Precise positioning of the electrodes usually results in adequate ankle movement balancing dorsiflexion with eversion. The lightweight cuff is only 5.5 cm high and is designed to provide optimal stability with minimal amount of skin coverage to increase wearing comfort over long periods of time. The cuff has a molded hard plastic insert, which facilitates proper positioning of the electrodes over the nerve and muscle from day to day.
To synchronize the stimulation with the swing phase of the gait cycle, the WalkAide uses a tilt sensor or a heel sensor. Thresholds for these sensors and other timing parameters are selected during an initial setup process during which the WalkAide is connected to a computer running custommade software. During the setup process, a therapist controls the timing of the stimulation delivered by the WalkAide by operating a hand switch, while the subject walks at a comfortable pace. At the same time, the signals from the heel and tilt sensors are recorded by the computer. Optimizing routines are used to match the timing based on the tilt signal with the stimulation periods indicated by the heel signal or manual switch. If necessary, the thresholds and timing parameters can be adjusted manually to fine-tune the timing. After the optimal parameters have been downloaded into the WalkAide, one or more sets of data are collected with the patient walking at varying speeds, showing the continuous heel and tilt signal data and the periods where the stimulator was on. The accuracy of the tilt-based timing can be assessed graphically by looking at the overlap of the "On" periods indicated by the 3 trigger modes (tilt, heel, manual) and by comparing the "On" periods with the continuous heel and tilt signal. The parameter settings for the tilt sensor are deemed satisfactory when there are no missing or extra triggers during normal walking, that is, the device fires one stimulus train for each step. Furthermore, the start and duration of the "On" periods correspond with the other trigger modes (heel and hand switch).
Walking Performance
The primary outcome measures were walking speed and physiological cost index (PCI), which is a commonly used measure of walking effort. 9, 11, 20 Walking speed was measured with a 10-m straight-line test. A 4-minute test around a 10-m figure-8 evaluated speed at a longer distance that included turns, and the concomitant effort expended. The subjects were asked to walk at their maximal safe speed for both walking tests. For the straight-line test, the time was measured for the subjects to cross 2 lines on the floor separated by 10 m, with 2 m at either end for acceleration to and deceleration from a steady walking speed. For the figure-8 test, the total distance walked in 4 minutes was measured. Both walking tests were performed with and without the stimulator turned on, which we refer to as FES On and FES Off. Each test session was started with the straight-line test that was performed twice with FES On and twice with FES Off, in a fixed order: Off-On-On-Off or On-Off-Off-On. Baseline testing was performed in the first order, but on successive visits the order was switched to minimize the effect of fatigue. The figure-8 tests were performed next, with FES Off first at baseline. The order of FES On and FES Off was also alternated for the figure-8 tests on successive visits. Subjects could not be blinded to whether the stimulation was on or off, because they could feel the stimulus and see their foot move. Similarly, the people measuring walking performance could not be blinded, because they too could observe the movements evoked by FES.
To calculate PCI, heart rate was registered with a Polar monitor every 15 seconds during the 4-minute figure-8 test, as well as 2 minutes before, and up to 4 minutes after. PCI is calculated as the difference between resting heart rate and active heart rate during walking (in beats/min), divided by the average walking speed (m/min) over the 4-minute walking period. The active heart rate was calculated as the average rate during the last 2 minutes of walking. The resting heart rate was calculated as the mean of the 2-minute rest period before the walking and the last 2 minutes of the rest period after walking. As the PCI calculations are sensitive to changes in resting heart rate, 21,22 a number of precautions were taken to ensure reliable resting values. Sufficient time was given to the subjects to make sure their heart rate settled down before the start of testing. The subjects sat in a comfortable chair with an arm rest and were asked to relax, and talking was avoided. Heart rate was monitored continually, and the actual recording of the initial resting values was only started when a stable heart rate was reached. The heart rate after walking typically reached prewalking resting values after 2 minutes of resting and was monitored for another 2 minutes. If necessary, the period was extended until the basal level from before walking was reached. Thus, the subjects were always at a resting heart rate before starting the next figure-8 test. The PCI may not be a good measure of effort in patients receiving medication that controls heart rate. However, we included all subjects in our PCI data, including the patients with known use of such medications, as analysis of their PCI data showed that their heart rates were still responsive to the periods of walking and rest.
Although the PCI is commonly used as a measure of effort in walking, it is not as reliable or sensitive as oxygen consumption measurements (Vo 2 ) as a measure of energy consumption. [21] [22] [23] Equipment to measure Vo 2 was not available at most of the centers, and the requirement for a large number of repeated measures meant that PCI was the only feasible method.
WalkAide Usage
In addition to walking performance, data were collected on usage of the WalkAide. The WalkAide keeps track of the number of hours per day that the device is on and the number of stimulus trains delivered per day. As each stimulus train normally represents 1 step, the device measures the number of steps taken with the device on a daily basis. The usage data were downloaded from the device each time the subject came in for testing. There was considerable day-to-day variability because some subjects did not wear the device on some days. Therefore, straight lines that minimized the least square error were fitted to the data over a period of about 100 days. Initial and final values for the percentage of days the WalkAide was used (per bin of 10 days), and for the number of hours/day and steps/day on the days it was used, were calculated from the fitted line at 0 and 100 days.
Data Analysis
All walking variables were analyzed for the effect of 3 factors, that is, Time, FES, and Group. The factor Time refers to the assessments from baseline (Time 0) up to 11 months. The factor FES refers to the data with FES On and Off. Group refers to the progressive and nonprogressive subject groups. To compare with other studies we defined 3 change scores for the different variables. Changes comparing FES On and Off at a given time are referred to as the orthotic effect. Changes over time (values at Time X -Time 0) are referred to as the therapeutic effect. We calculated the therapeutic effect for both the FES On and FES Off conditions. Finally, the combined orthotic and therapeutic effect, briefly referred to as the combined effect, was calculated as (values at Time X with FES On) -(values at Time 0 with FES Off).
Statistical analysis was performed using software from SPSS Inc (Chicago, IL). Generally, a 3-way ANOVA with 2 repeated factors (Time and FES) and 1 group factor (Group) was performed first to examine the main effects and interactions. When necessary, 2-way or 1-way independent or repeated-measures ANOVAs were performed afterward for more specific comparisons. For each ANOVA, sphericity was assessed using Mauchly's test. When the condition of sphericity was not met (P < .05), Greenhouse-Geisser or Huynh-Feldt corrected statistics were used if the estimate of sphericity (epsilon) was respectively <.75 or >.75. For multiple comparisons, Bonferroni or Sidak corrected post hoc tests were used. For 1-way independent ANOVAs, the Brown-Forsythe corrected statistics were used when the homogeneity of variances criterion was violated, and Hochberg's GT2 procedure was used for the post hoc tests when sample sizes were very different. Full statistical details are presented in this article only once. F values and degrees of freedom for the ANOVAs are omitted in the text when they are given in the figures and tables. P values >.05 are reported in the text as NS (nonsignificant) when available as a number in figures and tables.
Results

Subjects
Descriptive statistics of the progressive and nonprogressive groups are given in Table 1 for the 73 subjects who completed at least 3 months of the study. Eleven other subjects dropped out of the study. Four subjects dropped out because of medical reasons (not related to the WalkAide) and 1 was too busy and could not make the time commitment. Two subjects gave up after, respectively, 1 and 2 months because they did not like the WalkAide or did not get enough benefit from it, and another subject dropped out after 2 months because of skin irritation under the electrodes. Within the nonprogressive group (n = 41), the largest number had a cerebrovascular accident (CVA, 26). Others had foot drop from an SCI (9), surgical complications (3), head injury (2), and cerebral palsy (1). The progressive group (n = 32) consisted of 31 subjects diagnosed with secondary progressive MS (rather than the relapsing-remitting form) and 1 with familial spastic paraparesis. The nonprogressive and progressive groups did not differ significantly in age or time since onset. The means ± standard deviations (SD) were, respectively, 52.0 ± 16.0 and 54.2 ± 9.8 years for age (F(1, 67.5) = 0.56; P = .46) and 10.7 ± 11.7 and 11.5 ± 8.6 years for time since onset of disease (F(1, 71) = 0.18; P = .73). All subjects lived independently at home, alone or with their family, and were able to walk in the community without assistance from other people. Some walked without aides; others used aides such as a cane, 2 elbow crutches, and 3 or 4 wheeled walkers, and a few with higher level of disability used a motorized scooter for longer distances.
To justify the pooling of the walking data for the subjects with CVA, SCI, and other conditions, we checked for differences between these subgroups in the nonprogressive group. Pooling was justified as 2-way mixed ANOVAs (FES × Condition) revealed no significant differences in any of the walking variables (figure-8 speed, straight-line speed, and PCI) between the subjects with CVA, SCI, and other conditions at baseline and 1, 2, and 3 months follow-up. The 1 subject with familial paraparesis was pooled together with the MS subjects into the progressive group.
Tilt Versus Heel Sensor Control
For 72 out of the 73 subjects, the tilt sensor was adequate to obtain good timing of the stimulation, according to the criteria explained in the Methods. Only 1 subject used the heel switch because he had a very stiff-legged gait, taking small steps with insufficient modulation in tilt to reliably trigger stimulation. Two others used a heel switch initially for the same reason, but then switched to a tilt sensor after a few weeks, as their walking pattern improved. Figure 1 shows the changes in walking performance over the first 3 months with FES On and Off for the progressive and nonprogressive groups. Figure 1A shows figure-8 walking speed for 40 nonprogressive and 32 progressive subjects. . This indicates that, on average, all subjects walked significantly faster with FES On than with FES Off (ie, orthotic effect) and that the orthotic benefit was similar in the nonprogressive and progressive groups. The mean absolute walking speeds (m/s) and percentage changes in mean speed are given in Table 2 . The nonprogressive group had a 5% orthotic benefit on figure-8 speed at baseline and at 3 months (Table 2 ). In the progressive group, the orthotic benefit was 2.3% at baseline and 5.7% at 3 months. In addition to the immediate orthotic effect of FES, prolonged use of the WalkAide also had a therapeutic effect, that is, figure-8 walking speed increased over time (main Time effect mentioned above). The therapeutic effect over the first 3 months was similar for FES On and Off (Time × FES, NS). Mean walking speed with FES On after 3 months was increased by 17.8% (from 0.50 to 0.59 m/s) in the nonprogressive group and by 12.6% (from 0.54 to 0.61 m/s) in the progressive group. The therapeutic effect at 3 months measured with FES Off was also 17.8% for the nonprogressive group and 9.1% for the progressive group. Although the increase in mean speed after 3 months was greater in the nonprogressive group than in the progressive group (especially with FES Off where the effect was nearly double), the 3-way ANOVA over all time points did not show a significant Time × Group interaction effect (P = .23) or a main Group effect (P = .66). The nonprogressive group had the largest increase in speed after 1 month of use (12% average for FES On and Off combined), whereas the increase was more gradual in the progressive group. However, Bonferroni corrected post hoc tests (for FES On/Off combined) showed that the therapeutic effect was already significant after 1 month use for both groups (nonprogressive P < .001; progressive P = .039). Figure 1B shows walking speed for the 10-m straightline test, which was available for 32 nonprogressive and 30 progressive subjects. The overall effects were similar to those for the figure-8 test. There was a significant orthotic effect (FES, P < .001) and therapeutic effect (Time, P < .001) on straight-line walking speed, with no interactions between Time, FES, and Group. The orthotic effect on straight-line walking speed at baseline and 3 months was, respectively, 4.3% and 5.9% in the nonprogressive group and 3.9% and 6.7% in the progressive group. The therapeutic effect with FES Off and On was, respectively, 12.0% and 13.7% for the nonprogressive group and 5.3% and 8.1% for the progressive group. Sidak corrected post hoc tests showed that the increase in speed with respect to baseline only became significant after 2 months (FES On/Off and both groups combined).
Walking Speed: 3-Month Follow-up
In Figure 2A , straight-line speed was plotted against figure-8 speed, measured at 3 months with FES Off, for 30 nonprogressive and 30 progressive subjects. Both speeds were highly correlated (r 2 = .89; P < .001), and the bestfitting linear regression line had a slope of .73, indicating that figure-8 speed was about 30% slower on average. The slopes were similar in both the nonprogressive and progressive groups, respectively, .75 (r 2 = .87) and .71 (r 2 = .91). Data would fall on the dashed unity line if the speeds were the same. However, between-subject variability was large, and the ratio of figure-8 to straight-line speed ranged from .5 to 1.0. Because the subjects were asked to walk at the maximal safe speed that they could maintain for both tests, the slower walking speeds obtained for the figure-8 tests may be attributed to the fact that the longer test requires endurance and the agility to make turns.
On average, the orthotic benefits for the straight-line and figure-8 speeds were comparable, whereas the therapeutic and combined effects were slightly higher for the figure-8 test ( Table 2) . To verify the trends in the mean values reported in Table 2 , we plotted the change in straight-line speed against the change in figure-8 speed for all subjects (combined effects at 3 months, see Figure 2B ). Changes in speed on both tests were highly correlated overall (r 2 = .58; P < .001), for the nonprogressive group (r 2 = .64; P < .001) and for the progressive group (r 2 = .49; P < .001). Figure 2B shows that the corresponding linear regression line (y = 0.57x + 9.39) does not go through the origin, which means that a simple multiplication factor is not sufficient to describe the relationship between the changes on both tests. Further analysis showed that the people with a 0% to 10% increase on the 10-m test had an increase on the figure-8 test that was on average about 3 times larger (mean ratio 3.2). People with a 10% to 20% increase on the 10-m test had a similar increase on the figure-8 (mean ratio 1.2), whereas people with 10-m test increases greater than 20% had relatively smaller figure-8 increases (mean ratio 0.8).
Walking Speed: 11-Month Follow-up
Within the nonprogressive and progressive groups, respectively, 31 and 29 subjects continued the trial up to 6 months (mean 5.5 months) and 14 and 19 subjects up to 11 months (mean 10.8 months). External factors influenced who could continue and the exact timing of the visits (see Study Design in Methods). To make sure there were no performance differences between the subjects who stopped using FES after 3 months and those who continued up to 6 and 11 months, we performed 2-way mixed ANOVAs for figure-8 speed with FES Off combining the first 4 time points (baseline, 1, 2, 3 months) and 3 subgroups with different lengths of follow-up (up to 3, 6, and 11 months). The statistics indicated that the subjects who continued to use the WalkAide longer were not necessarily those who benefited most over time (Time × Follow-up-length: nonprogressive, F(4.9, 91) = 1.2, P = .31; progressive, F(4.58, 66) = .29, P = .91) or walked faster (or slower) to begin with (Follow-up-length: nonprogressive, F(2, 37) = 1.5, P = .23; progressive subjects, F(2, 29) = .19, P = .82). The effects were similar for figure-8 speed with FES On. Analysis of the PCI data also showed similar results, that is, no interaction effect between Time and Follow-up-length and no difference between the groups with different Follow-up periods. Figure 3 compares changes in figure-8 walking performance for the subjects who used the WalkAide for 11 months. In agreement with the data for the 3-month followup, the orthotic (FES, P < .001) and therapeutic effects (Time, P < .001) were significant for figure-8 walking speed. The orthotic effect was again similar for the nonprogressive and progressive groups (FES × Group, NS) and similar for all time points (Time × FES, NS). The orthotic effects at baseline and 11 months were, respectively, 9.8% and 7.6% in the nonprogressive group and 4.3% and 4.8% in the progressive group. In contrast to the 3-month followup, the therapeutic effect over 11 months was different for the nonprogressive and progressive groups (Time × Group, P = .039). Figure 3 shows how both groups increased in walking speed over the first 3 months of WalkAide use, but then diverged. The nonprogressive group kept improving, whereas the progressive group reached a plateau. Although the traces became quite separated over time, there was no significant difference in walking speed between both groups (main Group effect, P = .52). The group effect was probably not significant because of the large between-subject variability in the data. A similar statistical analysis on the normalized data (all values normalized to the walking speed at Time 0 with FES Off) resulted in a highly significant main group effect (P = .005).
Separate 2-way ANOVAs (Time × FES) showed that the overall therapeutic effect was significant not only for the nonprogressive group (Time, P < .001) but also for the progressive group (Time, P = .021). The therapeutic effect at 11 months with FES Off and On was, respectively, 28.0% and 25.5% for the nonprogressive group and 7.9% and 8.4% for the progressive group (Table 2) . Bonferroni corrected pairwise comparisons showed that increases compared with baseline only became significant at 6 months (P = .018) in the nonprogressive group. Whereas the overall statistic showed a therapeutic effect for the progressive group, none of the pairwise contrasts were significant. The overall trends for the 10-m straight-line walking speed were very similar to the figure-8 speed in the group who used the WalkAide for 11 months, and therefore the data were not included in 
Physiological Cost Index
The PCI for the nonprogressive group was generally higher (mean ± SEM, 0.92 ± 0.10 beats/m at baseline) than for the progressive group (0.8 ± 0.08 beats/m), but 3-way mixed ANOVAs for the 3-month follow-up data revealed that the differences were not significant (main Group effect, NS; see Figure 1C ). There was no significant orthotic effect on PCI (FES, NS), but there was a therapeutic effect. Overall, the PCI significantly decreased over the first 3 months of WalkAide use (Time, P = .031), and the trend was similar for the nonprogressive and progressive groups (Group × Time, NS). The therapeutic effect with FES Off and On was, respectively, -6.8% and -6.6% in the nonprogressive group and -3.0% and -8.7% in the progressive group. The decrease in PCI over time indicates that with prolonged WalkAide use both groups of patients used less effort while walking faster.
In the subset of subjects with an 11-month follow-up, the trends in PCI over time were different for the nonprogressive (n = 13) and progressive groups (n = 18, Time × Group, P = .039). Separate 2-way ANOVAs (Time × FES) per group showed that the PCI significantly decreased over time in the nonprogressive group (Time, P = .039). PCI was 15.9% and 18.6% lower at 11 months compared with baseline for walking with FES Off and On, respectively. The PCI data were less consistent over time for the progressive group and did not show a general decreasing trend (Time, NS). Because of the large variability between subjects, neither the pairwise comparisons between time points nor the difference between PCI with FES On or Off were significant. Table 2 ). At later times the effects diverged between the nonprogressive and progressive groups, to a 29.9% and 12.5% increase respectively, at 6 months (F(1, 29) = 38.3; P < .001 and F(1, 28) = 16.8, P < .001) and 37.8% and 13.1% at 11 months (F(1, 13) = 23.8, P < .001 and F(1, 18) = 7.9, P = .012). The combined effect on PCI in the nonprogressive group increased from -7.1% (F(1, 37) = 2.5; P = .12) at 3 months to -11.1% (F(1, 25) = 2.8, P = .11) and -18.2% (F(1, 12) = 5.4, P = .038) at 6 and 11 months, respectively. The combined effect on PCI in the progressive group at 3, 6, and 11 months was, respectively, -8.7%, -2.4%, and 
Combined Orthotic and Therapeutic Effect on Walking Speed and PCI at 3, 6, and 11 Months
Usage
The WalkAide was used intensively from the beginning of the trial, and the number of days used did not change over time (Time, NS; see Table 3 ). The progressive group used the WalkAide during more days than the nonprogressive group, 85.0 ± 2.6% versus 73.4 ± 4.2% of the days (mean ± SEM, Group, P = .037). However, the number of hours per day of use increased significantly over time for both groups, on average from 7.4 ± 0.5 h/day to 9.6 ± 0.5 h/day (Time, P = .002) and was again higher for the progressive group than for the nonprogressive group, respectively, 9.2 ± 0.5 h/ day versus 7.3 ± 0.6 h/day (Group, P = .038). The number of steps per day of use was similar for both groups (Group, NS) and increased significantly over time from 1842 ± 198 steps/day to 2110 ± 204 steps/day (average for both groups, Time, P = .019). A typical stride length for our population was close to 1 m, so subjects were walking about 2 km/day with the device.
Discussion
Orthotic Effect
This multicenter trial showed that mean walking speed was on average 5.7% higher (ranging from 2.3% to 9.2% over all time points and for the figure-8 and 10-m test) with FES On compared with FES Off in subjects with foot drop because of various lesions of the CNS. No significant difference was observed between subjects with progressive and nonprogressive disorders or between time points. Table 4 summarizes the results for 12 studies that reported orthotic, therapeutic, or combined effects of FES on walking speed for different pathologies. The results are fairly consistent across the studies for the orthotic and combined effects. The orthotic benefit for people with a stroke ranged from 6% to 22% and for people with SCI from 7% to 21%. Only 2 previous articles have studied the effect of a foot drop stimulator on walking performance in people with chronic progressive diseases such as MS. Taylor et al 12 examined 21 subjects with MS and found an orthotic effect with 16% improvement in walking speed and 24% reduction in effort as measured by the PCI. Paul et al 24 studied 12 patients with MS who had used a foot drop stimulator for at least 6 months and found an orthotic effect with a 15% increase in speed and 12% reduction in PCI. In conclusion, our results support previous studies in showing an orthotic effect in all patients, irrespective of the cause of the foot drop, and provide the additional information that the orthotic effect does not change with time over a prolonged period (11 months).
Kim et al 4 found another interesting result, namely, that the orthotic effects of FES and a hinged AFO were similar in people with incomplete SCI when tested in a single session and that these could be combined to give a better walking performance. Despite the fact that the use of an AFO is considered to be the standard of care for correction of foot drop, only 1 study to our knowledge is available in MS that has examined the effect of an AFO on walking performance. Sheffler et al 25 significant improvement in performing timed tasks of functional ambulation with an AFO. Their results indicate that people with MS may benefit more from a foot drop stimulator than from an AFO.
tested 15 patients with MS and found no
Therapeutic and Combined Effects
In addition to the orthotic effect, an increase of walking speed even after turning the stimulation off (therapeutic effect) has been observed in several studies following the original report of Liberson et al. 5 A meta-analysis by Robbins et al 17 focused on this effect of electrical stimulation on walking speed in stroke patients, as presented in 8 studies. However, only 3 controlled FES studies were included in the effect model analysis, covering a total of 36 patients in the FES intervention groups (2 studies were uncontrolled trials, and 3 studies used low-level electrical stimulation during short treatment sessions without walking, ie, TENS). The mean increase in walking speed over time was 0.18 m/s (95% confidence interval = 0.08-0.28 m/s). However, the pooled therapeutic effect has to be interpreted with caution. In 2 of the 3 studies, 31,32 the patients received short stimulation sessions of 10 to 60 minutes, once or twice per day, rather than using the foot drop stimulator all day while walking in the community. One of these studies actually applied the stimulation to the arm rather than the leg! 27 Also, the duration of the trials was limited to only 3 weeks and 2 months, respectively, whereas we have shown that therapeutic changes grow over many months. Furthermore, all 3 studies only used short distance walking tests (10-20 m), which may underestimate potential changes on longer distances that are more relevant to activities of daily living (see below). Another systematic review 19 (see Table 4 ) uses the term orthotic effect in the title but appears to be measuring what we call a combined effect. The authors report a pooled increase in walking speed for 116 subjects of 38%. However, they include studies on acute and subacute patients as well as studies that use multichannel stimulators and implanted devices. Thus, although their values show agreement with other studies including ours, the results must be treated cautiously.
A review by Burridge et al 15 presented results of 16 articles on both the orthotic and therapeutic effects of peroneal nerve stimulation for foot drop mainly in stroke patients. However, this review was descriptive in nature, and study data were not pooled. Several more recent studies have been published subsequently and have been included in the text and in Table 4 . The combined effect on walking speed ranged from 18% to 34% improvement in stroke and from 19% to 54% in SCI. In comparison, our study showed a combined effect of 38% increase in nonprogressive subjects after 11 months, which is in good agreement with previous studies. The published results are less consistent for the therapeutic effect. The 2 available randomized controlled trials in stroke subjects showed no therapeutic effect, whereas 4 uncontrolled studies showed therapeutic effects ranging from 12% to 16%. Two studies reported a 12% to 28% therapeutic effect in SCI subjects. Most studies reported the therapeutic and combined effects for a limited time and at a single time point, that is, 3, 4.5, or 6.5 months, without documenting changes over time. Our results for nonprogressive subjects are comparable with previous studies over a period of 3 months (18%), but the therapeutic effect continued to increase to 28% at 11 months. The study by Wieler et al 11 collected data for a longer period (up to 3 years; see also Kralj et al 28 and Swain and Taylor 29 for longer term studies), but all data from 3 months up to 3 years were averaged. The therapeutic effect of Wieler et al 11 (28% in SCI subjects) was the largest previously reported and is consistent with the idea that previous studies did not follow subjects long enough to observe the full therapeutic effect of using a foot drop stimulator. A more recent study by Burridge et al 18 tested stroke patients with an ActiGait implanted stimulator up to 15 months and reported speed changes consistent with a therapeutic effect of 12% at 11.6 months (mean final assessment time).
Our results showed that the 4-minute figure-8 test and the 10-m straight-line test revealed similar trends in walking speed with regard to the factor Time and FES On or Off over a 3 and 11 month follow-up period. However, the shorter 10-m test underestimated the increases on the longer figure-8 test for people with relatively small increases or even decreases on the 10-m test ( Figure 2B ) and, vice versa, overestimated the figure-8 increases for people with large 10-m test increases. The reasons for these differences are not known, but the results suggest that a short walking test might not be a good predictor of the potential improvements over the longer distances that are more important for activities of daily living. Longer walking tests should be included in test protocols for assessing the effect of devices to improve walking.
Progressive Versus Nonprogressive Disorders
All but one previous study describing the therapeutic effect used subjects who had lesions caused by single events, such as a stroke or SCI, where no further progression of the disability was expected. Taylor et al 12 also included subjects with MS. In contrast to stroke and SCI, no therapeutic effect was detected in the group of MS subjects as a whole. These findings suggested a potentially important difference between nonprogressive disorders such as stroke and SCI and progressive disorders such as MS.
We included several groups with nonprogressive disorders as well as a substantial number of people with MS. Although the ages and times since onset were different in our study between the various, generally nonprogressive conditions, the walking performance was similar at all time points. This provided a justification for combining the nonprogressive subgroups. Our data also showed that the increases were not significantly different between the progressive and nonprogressive groups in the first 3 months of treatment. This suggests that the nature of the physical deficit (foot drop) was more important than the etiology in determining the early response to treatment. In contrast to the results of Taylor et al, 12 a clear therapeutic effect was seen in the progressive group as well as the nonprogressive group during the first 3 months.
The walking speeds for the 2 groups diverged after 3 months of FES use. Whereas the nonprogressive group continued to increase speed with and without stimulation, a plateau of gait speed with a tendency to a decline in speed and a corresponding increase in the PCI occurred in the progressive group as a whole (Figure 3 ). Any changes toward the initial levels may be due to the progressive nature of the disease causing some of the early gains to be lost. The decrease in walking speed may also have resulted from weakening of other muscle groups that were not being stimulated. Taylor et al 12 studied their MS subjects at 4.5 months, whereas we saw the largest improvements at 3 months. Also, the progressive subjects with MS in our study were diagnosed as having the secondary progressive rather than the relapsing-remitting form of the disease. Taylor et al did not include detailed clinical information on the type of MS for their subjects. If they included subjects with the relapsingremitting form of MS, it would have made it very difficult to determine overall trends.
In response to the first question raised in the Introduction, we conclude that subjects with both progressive and nonprogressive disorders show a therapeutic effect of using foot drop stimulators. In response to the second question, an important new finding is that the benefits in the nonprogressive disorders continue to increase up to at least a year, whereas the therapeutic effects in progressive disorders appear to be largest at about 3 months and then may be offset by the progression of the disease process.
Control Methods and Usage
In all previous studies except those from our group, subjects used a heel sensor for control. In 72 of the 73 subjects, we achieved satisfactory timing of the stimulation by using the tilt sensor. The simplicity of a built-in tilt sensor and electrodes (no external wires or telemetry required) may have contributed to the extensive use of the foot drop stimulator in this study. The daily routine of putting on the WalkAide is simplified as the subjects only have to put on 1 device.
The subjects in the present study showed a remarkable compliance, using the stimulator on 80% of the days as documented by the recorded usage data ( Table 3 ). The duration of daily stimulation and the number of steps increased in both subject groups. One reason for the high usage may be the reduced effort required for walking, as documented by the decreased PCI. In contrast to AFOs, subjects generally recognize FES as an active movement that can strengthen their muscles; this may enhance their motivation to continue and even increase use. In particular, MS subjects have been reported to be highly motivated with low dropout rates in using FES devices. 12 In part, this may result from the negative prognosis of a progressive disorder such as MS. Any improvement in daily activities such as walking is most welcome, even if only for a limited period of time. Despite a tendency to decline after the first 3 months, the walking speed with FES was still greater after nearly a year than at the initial assessment without FES. If progressive subjects can remain ambulatory in their own home and not become dependent on wheelchairs and/or assisted living facilities, costs for health care and social services can be reduced and the quality of life can be enhanced.
